KYTHERA Biopharmaceuticals (KYTH) Files $86.25M IPO
Tweet Send to a Friend
Up)
KYTHERA Biopharmaceuticals, Inc. (Nasdaq: KYTH) filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering amount its $86.25 million. KYTHERA plans to list on the Nasdaq under the ticker "KYTH."
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Leerink Swann, and Lazard Capital Markets.
KYTHERA Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The offering is being made through J.P. Morgan, Goldman, Sachs & Co., Leerink Swann, and Lazard Capital Markets.
KYTHERA Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Channeladvisor (ECOM) Takes Breather after Rip Roaring IPO Debut
- Tableau Software (DATA) IPO Surges Higher
- Global Brass and Copper (BRSS) IPO Opens Higher
Create E-mail Alert Related Categories
IPOsRelated Entities
JPMorgan, Lazard
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
